Nautilus Biotechnology is trading at $2.97, a change of -5.41%; broad technology weakness is the likeliest explanation, though no report directly links it to the after-hours move.
- No new company-specific catalyst was identified for October 29; the Q3 report and grant announcement were released October 27.
- The Nasdaq Composite fell 1.4% and the S&P 500 fell 0.3% during Thursday’s session, as AI-spending concerns pressured tech shares.